AATD market seen reaching $9.7B by 2033

By AI, Created 10:05 AM UTC, May 20, 2026, /AGP/ – The global alpha-1 antitrypsin deficiency market is projected to grow from $4.2 billion in 2026 to $9.7 billion by 2033, driven by rising respiratory disease diagnoses, new therapies and broader use of genetic testing. North America is expected to lead the market in 2026, while Asia Pacific is forecast to grow fastest.

Why it matters: - Alpha-1 antitrypsin deficiency, or AATD, is still widely underdiagnosed, so market growth is tied to more patients being found and treated. - The expansion reflects demand for rare-disease diagnostics, specialty care and advanced therapies for COPD, emphysema and other respiratory disorders. - Higher use of digital health tools and remote monitoring could make long-term care easier to deliver outside major hospital systems.

What happened: - Persistence Market Research projected the global AATD market at US$ 4.2 billion in 2026 and US$ 9.7 billion by 2033. - The forecast implies a 12.7% compound annual growth rate from 2026 to 2033. - The report identified augmentation therapy, gene therapy, RNA-based treatments, genetic testing and remote monitoring as key market segments. - The release was dated May 6, 2026.

The details: - Augmentation therapy is expected to hold about 41% of revenue in 2026. - Gene and RNA-based therapies are projected to be the fastest-growing treatment segment through 2033. - Genetic testing is expected to account for 39% of diagnostics revenue in 2026. - Remote monitoring is forecast to grow at a 14.2% CAGR, supported by telehealth adoption. - Hospitals are projected to hold about 46% of revenue in 2026. - Specialty clinics and home healthcare are expected to post the fastest growth among care settings. - North America is expected to lead with a 42% market share in 2026. - Asia Pacific is projected to grow fastest at a 13.1% CAGR through 2033. - The market is also seeing strategy shifts including novel delivery technology launches, biotech partnerships and expansion into Asia Pacific and Latin America. - The report’s segmentation also includes biomarker testing, pulmonary function monitoring, imaging, small molecules and advanced biologics.

Between the lines: - The market outlook is being lifted by better detection, not just more treatment options. - AATD remains missed in many patients, which means testing algorithms and outreach programs can expand the addressable market. - High treatment costs and uneven reimbursement remain major barriers, especially in low- and middle-income countries. - Rare-disease drug development is benefiting from regulatory incentives such as FDA Fast Track and Orphan Drug designations. - Competition is moving toward partnerships, acquisitions and clinical collaborations as companies chase later-stage assets.

What’s next: - Late-stage approvals for gene and RNA-based therapies could accelerate the market’s growth rate. - Broader telehealth reimbursement may further support remote monitoring and decentralized care. - Emerging markets including China, India and Brazil are expected to gain share as healthcare infrastructure improves. - More diagnostics and specialty clinic expansion could increase early identification and treatment initiation. - Key players cited in the market include Grifols, CSL Behring, Takeda, Kamada and Baxter.

The bottom line: - AATD is shifting from a niche rare-disease category into a broader growth market powered by better testing, new therapies and wider care access.